Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline

Gian Benedetto Melis, Valerio Mais, Anna Maria Paoletti, Fausta Beneventi, Marco Gambacciani, Piero Fioretti

Research output: Contribution to journalArticle

Abstract

To evaluate the efficacy of a single oral administration of the new ergot derivative Cabergoline in the prevention of postpartum lactation, we compared the effects of three different doses of the drug with those of placebo in 32 puerperal women. In a controlled, double-blind trial, the subjects were randomly allocated to four treatment groups receiving either placebo or 400, 600, or 800 μg Cabergoline (N = 8 in each group) within 24 hours after delivery. Treatment efficacy was assessed clinically by physical examination before (day 0) and at one, two, three, four, and 14 days after treatment. Plasma prolactin (PRL) concentrations were measured in blood samples collected before and at one, two, three, and four days after treatment. Lactation was prevented in four of the eight subjects (50%) who received 400 μg Cabergoline and in all subjects who received 600 or 800 μg Cabergoline. By contrast, only one of the eight subjects (12.5%) receiving placebo showed no signs of spontaneous lactation within the 14 days after delivery. No effects of placebo administration on plasma PRL levels were observed. Plasma PRL concentrations were significantly reduced starting from one day after Cabergoline administration, however, and the amount of inhibition of PRL secretion induced by different doses of the drug was not statistically different. These preliminary data demonstrate that Cabergoline has a dose-related effect in the prevention of postpartum lactation, and milk secretion can be prevented completely by a single oral administration of 600 or 800 μg of the drug.

Original languageEnglish
Pages (from-to)311-314
Number of pages4
JournalObstetrics and Gynecology
Volume71
Issue number3
Publication statusPublished - 1988

Fingerprint

Lactation
Prolactin
Oral Administration
Pharmaceutical Preparations
Placebos
Postpartum Period
Placebo Effect
Physical Examination
cabergoline
Milk
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline. / Melis, Gian Benedetto; Mais, Valerio; Paoletti, Anna Maria; Beneventi, Fausta; Gambacciani, Marco; Fioretti, Piero.

In: Obstetrics and Gynecology, Vol. 71, No. 3, 1988, p. 311-314.

Research output: Contribution to journalArticle

Melis, GB, Mais, V, Paoletti, AM, Beneventi, F, Gambacciani, M & Fioretti, P 1988, 'Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline', Obstetrics and Gynecology, vol. 71, no. 3, pp. 311-314.
Melis, Gian Benedetto ; Mais, Valerio ; Paoletti, Anna Maria ; Beneventi, Fausta ; Gambacciani, Marco ; Fioretti, Piero. / Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline. In: Obstetrics and Gynecology. 1988 ; Vol. 71, No. 3. pp. 311-314.
@article{bab8527a39c54ef7ac0b92e988877388,
title = "Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline",
abstract = "To evaluate the efficacy of a single oral administration of the new ergot derivative Cabergoline in the prevention of postpartum lactation, we compared the effects of three different doses of the drug with those of placebo in 32 puerperal women. In a controlled, double-blind trial, the subjects were randomly allocated to four treatment groups receiving either placebo or 400, 600, or 800 μg Cabergoline (N = 8 in each group) within 24 hours after delivery. Treatment efficacy was assessed clinically by physical examination before (day 0) and at one, two, three, four, and 14 days after treatment. Plasma prolactin (PRL) concentrations were measured in blood samples collected before and at one, two, three, and four days after treatment. Lactation was prevented in four of the eight subjects (50{\%}) who received 400 μg Cabergoline and in all subjects who received 600 or 800 μg Cabergoline. By contrast, only one of the eight subjects (12.5{\%}) receiving placebo showed no signs of spontaneous lactation within the 14 days after delivery. No effects of placebo administration on plasma PRL levels were observed. Plasma PRL concentrations were significantly reduced starting from one day after Cabergoline administration, however, and the amount of inhibition of PRL secretion induced by different doses of the drug was not statistically different. These preliminary data demonstrate that Cabergoline has a dose-related effect in the prevention of postpartum lactation, and milk secretion can be prevented completely by a single oral administration of 600 or 800 μg of the drug.",
author = "Melis, {Gian Benedetto} and Valerio Mais and Paoletti, {Anna Maria} and Fausta Beneventi and Marco Gambacciani and Piero Fioretti",
year = "1988",
language = "English",
volume = "71",
pages = "311--314",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline

AU - Melis, Gian Benedetto

AU - Mais, Valerio

AU - Paoletti, Anna Maria

AU - Beneventi, Fausta

AU - Gambacciani, Marco

AU - Fioretti, Piero

PY - 1988

Y1 - 1988

N2 - To evaluate the efficacy of a single oral administration of the new ergot derivative Cabergoline in the prevention of postpartum lactation, we compared the effects of three different doses of the drug with those of placebo in 32 puerperal women. In a controlled, double-blind trial, the subjects were randomly allocated to four treatment groups receiving either placebo or 400, 600, or 800 μg Cabergoline (N = 8 in each group) within 24 hours after delivery. Treatment efficacy was assessed clinically by physical examination before (day 0) and at one, two, three, four, and 14 days after treatment. Plasma prolactin (PRL) concentrations were measured in blood samples collected before and at one, two, three, and four days after treatment. Lactation was prevented in four of the eight subjects (50%) who received 400 μg Cabergoline and in all subjects who received 600 or 800 μg Cabergoline. By contrast, only one of the eight subjects (12.5%) receiving placebo showed no signs of spontaneous lactation within the 14 days after delivery. No effects of placebo administration on plasma PRL levels were observed. Plasma PRL concentrations were significantly reduced starting from one day after Cabergoline administration, however, and the amount of inhibition of PRL secretion induced by different doses of the drug was not statistically different. These preliminary data demonstrate that Cabergoline has a dose-related effect in the prevention of postpartum lactation, and milk secretion can be prevented completely by a single oral administration of 600 or 800 μg of the drug.

AB - To evaluate the efficacy of a single oral administration of the new ergot derivative Cabergoline in the prevention of postpartum lactation, we compared the effects of three different doses of the drug with those of placebo in 32 puerperal women. In a controlled, double-blind trial, the subjects were randomly allocated to four treatment groups receiving either placebo or 400, 600, or 800 μg Cabergoline (N = 8 in each group) within 24 hours after delivery. Treatment efficacy was assessed clinically by physical examination before (day 0) and at one, two, three, four, and 14 days after treatment. Plasma prolactin (PRL) concentrations were measured in blood samples collected before and at one, two, three, and four days after treatment. Lactation was prevented in four of the eight subjects (50%) who received 400 μg Cabergoline and in all subjects who received 600 or 800 μg Cabergoline. By contrast, only one of the eight subjects (12.5%) receiving placebo showed no signs of spontaneous lactation within the 14 days after delivery. No effects of placebo administration on plasma PRL levels were observed. Plasma PRL concentrations were significantly reduced starting from one day after Cabergoline administration, however, and the amount of inhibition of PRL secretion induced by different doses of the drug was not statistically different. These preliminary data demonstrate that Cabergoline has a dose-related effect in the prevention of postpartum lactation, and milk secretion can be prevented completely by a single oral administration of 600 or 800 μg of the drug.

UR - http://www.scopus.com/inward/record.url?scp=0023736988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023736988&partnerID=8YFLogxK

M3 - Article

C2 - 3279351

AN - SCOPUS:0023736988

VL - 71

SP - 311

EP - 314

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 3

ER -